Newsroom

Revisiting the nature and pharmacodynamics of tacrolimus metabolites

September 27, 2024

September 27, 2024

New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI

September 23, 2024

September 23, 2024

New Treatment Insights into Switching to UZEDY® from Perseris®

September 23, 2024

September 23, 2024

2024 Annual General Meeting (French)

September 13, 2024

Reporting of the 2024 Annual General Meeting

September 13, 2024

September 13, 2024

Presentation at the H.C. Wainwright 26th Annual Global Investment Conference (New York, September 9 to 11)

September 5, 2024

September 5, 2024

Olanzapine LAI: No PDSS Observed After Completion of c.99% of the Targeted Injections for Submission

September 5, 2024

September 5, 2024

FY2023-24 Earnings Call

September 4, 2024

Progress in the Development of the Products Portfolio and the R&D Pipeline

September 3, 2024

September 3, 2024

Participation terms in the Combined General Meeting

August 26, 2024

August 26, 2024

Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine LAI and UZEDY® commercial progress

July 31, 2024

July 31, 2024

Medincell to Present Data Showing Enhanced Potential of Tumor-Targeting Monoclonal Antibody in Melanoma Using BEPO® Technology at he CRS Annual Meeting

July 1, 2024

July 1, 2024